For research use only
| Cat No. | ABC-RC026Y |
| Product Type | Recombinase Stable Cell Line |
| Cell Type | B Lymphocyte |
| Species | Human |
| Host Cell | RPMI-8226 |
| Source Organ | Peripheral Blood |
| Disease | Myeloma |
| Storage | Liquid Nitrogen |
RPMI-8226/Cre Stable Cell Line by AcceGen enables efficient gene recombination and conditional knockout studies for advanced multiple myeloma research.
RPMI-8226/Cre Stable Cell Line is a genetically engineered human multiple myeloma model derived from RPMI-8226 cells, featuring stable expression of Cre recombinase. The cell line maintains characteristic plasma cell morphology and multiple myeloma surface markers (CD38, CD138) while providing efficient genome editing capability through Cre-mediated recombination of loxP-flanked genes. This makes it an essential tool for conditional knockout studies, functional genomics, and pathway analysis in hematological malignancies. Applications include investigating gene function, signaling pathways, tumor progression, and mechanisms of drug resistance. The cells are cryopreserved at low passage (<P20) to ensure stable Cre activity and consistent performance. All lots are rigorously tested to be free from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Species | Human |
| Cat.No | ABC-RC026Y |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | B Lymphocyte |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Myeloma |
| Biosafety Level | 2 |
| Storage | Liquid Nitrogen |
| Product Type | Recombinase Stable Cell Line |
| Host Cell | RPMI-8226 |
| Gene Info | Cre Recombinase |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The RPMI-8226/Cre Stable Cell Line is engineered for conditional gene manipulation in multiple myeloma research. This model stably expresses Cre recombinase, enabling precise editing of loxP-flanked target genes in the RPMI-8226 background. The cell line is optimized for studying gene function in myeloma pathogenesis, validating therapeutic targets, and investigating drug resistance mechanisms. With consistent Cre activity and maintained myeloma characteristics, it provides a reliable platform for advanced genetic studies in hematological malignancy research.